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Background: Increased oxidative stress upregulates matrix metalloproteinases (MMPs) and transforming
grow factor (TGF–β), which are involved in hypertensive cardiac remodeling. We tested the hypothesis
that tempol (an antioxidant) could prevent these alterations in two-kidney, one-clip (2K1C) hypertension.
Methods: Sham-operated or hypertensive rats were treated with tempol (18 mg.kg−1 day−1 or vehicle) for
8 weeks. Systolic blood pressure was monitored weekly. At the end of the treatment, a catheter was inserted
into the left carotid artery and into the left ventricle (LV) to assess arterial blood pressure and contractile
function. Morphometry of the LV was carried out in hematoxylin/eosin sections and ﬁbrosis was assessed
in picrosirius red-stained sections. Cardiac TGF-β level was evaluated by immunoﬂuorescence. Cardiac
MMP-2 levels and activity were determined by gelatin zymography, in situ zymography, and immunoﬂuores-
cence. Cardiac superoxide production was evaluated by dihydroethidium probe.
Results: Tempol treatment attenuated 2K1C-induced hypertension and reversed the contractile dysfunction in
2K1C rats. Cardiac hypertrophy was ameliorated by antioxidant treatment. Hypertensive rats showed increased
cardiac MMP-2 levels, however tempol did not decreaseMMP-2 levels. Increased TGF-β level, total gelatinolytic
activity and oxidative stress were found in untreated 2K1C rats. Tempol treatment decreased oxidative stress,
TGF-β levels, and gelatinolytic activity in 2K1C rats to control levels.
Conclusions: Tempol blunted the increases in TGF-β, the proteolytic imbalance, and the morphological and func-
tional alterations found in 2K1C-induced cardiac hypertrophy. These ﬁndings are consistent with the idea that
antioxidants may help to prevent hypertension-induced cardiac hypertrophy.
© 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license. 1. Introduction
Chronic hypertension-induced left ventricular hypertrophy (LVH)
usually progresses to a decompensated stage and heart failure [1–3],
whichmay result of alteredmyocardial collagen matrix and ventricular
remodeling [4,5]. Indeed, hypertension-induced progressive accumula-
tion of interstitial collagen ﬁbers may disrupt myocyte alignment and
impair cardiac contractile function [4,6]. In this respect, growing evi-
dence indicates that matrix metalloproteinases (MMPs) are involved
in the progression of cardiac hypertrophy to heart failure [7,8]. These
enzymes degrade ﬁbrillar collagen and contribute to cardiacMorphology, Estomology and
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nder the Elsevier OA license. dysfunction and left ventricle remodeling in hypertension [3,9]. Impor-
tantly, MMP-2 overexpression induced severe ventricular remodeling
and systolic dysfunction in absence of superimposed injury [10], and
this effect may be a result of MMP-2 activity affecting intracellular tar-
gets, possibly impairing myocardial contractility [11,12].
Imbalanced MMPs activities result in deposition of extracellular
matrix modulated by increased expression of transforming grown
factor-β (TGF-β) [13,14], an important mechanism for transition of ﬁ-
broblasts to myoﬁbroblasts, thus promoting ﬁbrosis [3]. In this regard,
increased MMPs and TGF-β levels were shown in LVH [2,3], and both,
MMPs and TGF-β, are activated by oxidative stress [14–17]. Therefore,
it is possible that antioxidant treatment abrogates cardiac oxidative
stress and prevents LVH by mitigating this pathogenic mechanism
[3,9,18,19].
Tempol is an antioxidant drug which showed protective effects in
many disease models including hypertension [20]. In fact, this promis-
ing drug inhibited ROS formation in vitro better than other antioxidants
[20,21]. In the present study, we hypothesized that the antioxidant ef-
fects exerted by tempol would be associated with lower TGF-β levels
166 E. Rizzi et al. / International Journal of Cardiology 165 (2013) 165–173and blunted MMPs activities in the hearts of 2K1C hypertensive rats,
which could explain protective effects of tempol against morphological
and functional cardiac alterations induced by 2K1C hypertension.
2. Methods
The authors of this manuscript have certiﬁed that they comply with the Principles
of Ethical Publishing in the International Journal of Cardiology.
2.1. Animals and treatments
Experimental protocols followed standards and policies of the University of Sao
Paulo's Animal Care and Use Committee and the animals received humane care. Male
Wistar rats (180–200 g) obtained from the colony at University of São Paulo were
maintained on 12-h light/dark cycle at 25 °C with free access to rat chow and water.
2K1C hypertension was induced in rats as previously described [22]. Brieﬂy, male
Wistar rats (180 g) were anesthetized using ketamine (100 mg/kg intraperitoneally)
and xylazine (100mg/kg intraperitoneally) and, after a midline laparotomy, a silver clip
with an internal diameter of 0.20 mmwasplaced around the left renal artery. Sham-operated
rats underwent the same surgical procedure, except for theplacement of the renal artery clip.
The animals (10 per group) were randomly assigned to 1 of 4 experimental groups as fol-
lows: 2K1C and sham groups that received vehicle (water); 2K1C and sham groups that
received tempol 18 mg/Kg/day (4-hydroxy-tempo; Sigma; diluted in water) by gavage
[23]. Treatment was started 2 weeks after 2K1C hypertension was induced and main-
tained for additional 8 weeks. Tail systolic blood pressure (SBP) was assessed weekly by
tail-cuff plethysmography, and rats were considered to be hypertensive when SBP was
higher than 160 mmHg, 2 weeks after the surgery.
2.2. Assessment of Left ventricular function
Eight rats of each group were anesthetized with tribromoethanol (250 mg/kg, in-
traperitoneally) after 8 weeks of treatment. Polyethylene catheters (Becton Dickinson
and Co, Sparks, MD) were inserted into the right femoral artery for the direct
measurement of arterial blood pressure. Another polyethylene catheter was inserted
into the right carotid artery, and was carefully introduced into the left ventricle for
measurement of left ventricular pressures. The arterial and ventricular catheters
were connected to pressure transducers (P23Gb; Statham, Hato Rey, PR) and the sig-
nals were properly ampliﬁed. Arterial and left ventricular pressures were sampled
continuously (1 kHz) on an IBM/PC equipped with an analog to digital interface
(DI-220; Dataq Instruments, Akron, OH). A computer program (Advanced CODAS;
Dataq Instruments) was used to analyze the data and extract beat-by-beat time series
of heart rate (HR) and mean arterial pressure (MAP).
The ﬁrst derivative of left ventricular pressure (dP/dt) was calculated and values of
the maximum rate of isovolumic pressure development (+dP/dtmax) and the maxi-
mum rate of isovolumic pressure decay (−dP/dtmax) were measured [24]. At the
end of the experiments, the hearts were harvested and washed in saline and the left
ventricle was frozen and stored at −80 °C until used for biochemical determinations.
2.3. Harvesting and preparation of the hearts
After 8 weeks of treatment the animals were weighed, anesthetized, and their tho-
racic cavity was opened to expose the still beating heart. The hearts were rapidly re-
moved, rinsed in ice cold 0.9% saline solution, blotted, weighed, and ﬁxed as a whole
in phosphate-buffered 10% formalin (pH 7.3) for histological study. Both ventricles
from each heart were isolated and cut into 2 fragments by a mid-ventricular coronal
section. Each block was serially cut in the same direction and 4-μm thick sections
were stained with hematoxylin and eosin. The left ventricular wall and septum thick-
ness, and the area corresponding to the left ventricular chamber were determined in
the ﬁrst 3 histological sections of each block. Morphometric analyses were carried
out with Image J software (http://rsb.info.nih.gov/nih-image/). Average myocytes di-
ameter was determined from 20 measurements in each ventricle, which were made
at a magniﬁcation of 400× in longitudinally oriented myoﬁbers. Myocyte diameter
was obtained in the region of the nucleus of those cells in which the nuclear envelope
was sharply deﬁned at both ends, which corresponds to the nucleus length and to its
position at an equal distance from the sides of the myocytes. A skilled observer blinded
to the treatment groups made the measurements with the Leica Qwin software (Leica
Imaging Systems Ltd, Cambridge, UK) in conjunction with a Leica microscope (Leica
DMR, Leica MicrosystemsWetzlar GmbH, Wetzlar, Germany), videocamera, and an on-
line computer. To estimate the volume fraction (%) of ﬁbrosis in picrosirius red-stained
sections, quantitative examination of the left ventricular and septum myocardium was
carried out on a medium power light-microscopic ﬁeld (X400). For each heart, 15 ﬁelds
per region per rat were randomly selected and analyzed using Leica Qwin software
(Leica Imaging Systems). The mean value was subsequently calculated.
2.4. Assessment of cardiac ROS
Dihydroethidium (DHE), a sensitive probe for superoxide (O2−) and other non-
superoxide ROS, was used to evaluate in situ production of these species. Brieﬂy, car-
diac tissues were embedded in Tissue-tek and then frozen and cut in serial 5 μm.Unﬁxed cryosections were incubated at room temperature, in the dark, with 30 μL
of DHE (10 μmol/L) for 30 min. Sections were examined by ﬂuorescence microscopy
(Leica imaging Systems Ltd., Cambridge, England) and the image was captured at
magniﬁcation of 400×. Red ﬂuorescence reﬂected superoxide and other ROS produc-
tion and was evaluated by using Image J software.
2.5. Immunoﬂuorescence to assess TGF-beta expression
For immunoﬂuorescence, heart was harvested as above and embedded in parafﬁn.
Immunolabelling was performed with the following primary antibody transforming
growth factors beta (polyclonal rabbit anti-transforming growth factor-b (TGF-b)1/2/ 3;
Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA; diluted 1:100]. Sections 5 μm thick
were placed on silane coated slides, deparafﬁnized, washed in PBS, and then submitted
to nonspeciﬁc antibody binding block. After, the sections were incubated (overnight)
with the primary antibody and red ﬂuorescence was visualized by adding a conjugated
anti-mouse secondary antibody (Texas red® anti-rabbit, Vector laboratories; 1:200) for
1 h in a dark humidiﬁed chamber. The red ﬂuorescence was evaluated using the ImageJ
software.
2.6. In situ zymography and immunoﬂuorescence to assess MMP-2 expression
MMPs activities in situweremeasured in frozen left ventricles (5 per group) using DQ
Gelatin (E12055, Molecular Probes, OR) as a ﬂuorogenic substrate. Brieﬂy, left ventricles
samples were embedded in Tissue Tek and cut into 5-μm sections with a cryostat. Sample
sections were incubated with 1.0 mg/mL DQ gelatin in Tris–CaCl2 buffer (50 mM Tris,
10 mMCaCl2, 1 mMZnCl2) in dark humidiﬁed chambers for 1 h. The sectionswere exam-
ined with ﬂuorescent microscopy (Leica Imaging Systems Ltd., Cambridge, England) and
the image was captured at magniﬁcation of 400×. Proteolytic activity was detected as
bright green ﬂuorescence, which indicates substrate breakdown, and was evaluated by
using ImageJ Program (National Institutes of Health). To evaluate MMP-2 expression,
5-μm tissue sections were incubated with mouse anti-MMP-2 monoclonal antibody
(MAB3308, Chemicon, USA,), for 1 h in a dark humidiﬁed chamber (at a 1:1000 dilution).
Red ﬂuorescence was visualized by adding a rhodamine-conjugated anti-mouse second-
ary antibody (1:200) (AP160P, Chemicon) for 1 h. To conﬁrm the speciﬁcity of antibodies,
the primary antibody was omitted and substituted by phosphate-buffered saline 1% BSA.
Rhodamine did not bind nonspeciﬁcally to the tissue sections. MMP-2 expression was
detected as bright red ﬂuorescence, and was evaluated using the ImageJ software.
2.7. Measurement of cardiac MMP-2 levels by gelatin zymography
In the present study, gelatin zymography of MMP-2 and MMP-9 from left ventricle
samples was performed as previously described [25]. These MMPs are separated by mo-
lecular weight after gel electrophoresis under denaturing conditions. Thereafter, the en-
zymes are refolded and the proteolytic activity of each form is visualized in the stained
zymograms. Brieﬂy, frozen left ventricle samples (10 per group)were homogenized in ex-
traction buffer (300 mL for each 0.1 g of left ventricle sample) containing 10 mM CaCl2,
50 mM Tris–HCl pH 7.4, 0.1% Brij, 0.15 M NaCl, 1 mM Phe (1,10 orto phenanthrolene),
1 mM phenylmethanesulphonylﬂuoride, and 1 mM N-ethylmaleimide. The samples
were placed on ice within a refrigerator for 20 h and then centrifuged at 10,000 g for
15 min. The protein content was measured using the Bradford method (Sigma). Thereaf-
ter, the samples were diluted 1:1 with sample buffer (ﬁnal concentration: 2% SDS,
125 mM Tris–HCl; pH 6.8, 10% glycerol, and 0.001% bromophenol blue), and subjected
to electrophoresis on 12% SDS-polyacrylamide gel electrophoresis co-polymerized with
gelatin (0.1%) as the substrate. After electrophoresiswas completed, the gelwas incubated
for 1 h at room temperature in a 2% Triton X-100 solution, and incubated at 37 °C for 40 h
in Tris–HCl buffer, pH 7.4, containing 10 mmol/L CaCl2. The gels were stained with 0.05%
Coomassie Brilliant Blue G-250, and then destained with 30% methanol and 10% acetic
acid. Gelatinolytic activities were detected as unstained bands against the background of
Coomassie blue-stained gelatin. Enzyme activity was assayed by densitometry using a
Kodak Electrophoresis Documentation and Analysis System 290 (Kodak, Rochester, NY).
Gelatinolytic activities were normalizedwith regards to an internal standard (fetal bovine
serum) to allow integral analysis and comparison. The forms ofMMP-2were identiﬁed as
bands at75, 72 and 64 KDa.
3. Statistical analysis
The results are expressed as means±SEM. Between-group compar-
isons were assessed by 2-way analysis of variance or by 1-way analysis
of variance followed by the Newman–Keuls Multiple Comparison Test.
A probability valueb0.05 was considered signiﬁcant.
4. Results
4.1. Tempol treatment improves 2K1C-induced hypertension
No differences were found in baseline systolic blood pressure (SBP)
among all groups. SBP increased progressively in 2K1C animals after
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pol treatment attenuated the increase in SBP in 2K1C rats by approxi-
mately 33% (Fig. 1A). Similar results were found when invasive arterial
blood pressure measurements were considered (Pb0.05 versus
untreated 2K1C group; Fig. 1B, C andD). Tempol treatment did not affect
arterial pressure of sham groups throughout the study period. No differ-
enceswere found in bodyweight andheart rate among the study groups
(data not shown).
4.2. Tempol treatment attenuates 2K1C-induced cardiac dysfunction
Fig. 2 showsmaximum ascending and declining rates of left ventric-
ular pressure (+dP/dT max and−dPdT max, respectively). Hyperten-
sion increased both +dP/dT and−dP/dT by approximately 34% when
compared with the sham group (Pb0.05). The tempol treatment
blunted these changes in+dP/dT and−dP/dT found in 2K1C hyperten-
sive rats (Pb0.05; Fig. 2).
4.3. Tempol treatment attenuates 2K1C-induced cardiac remodeling
Fig. 3A shows representative photomicrographs of transverse heart
sections. We found increased heart weight/body weight ratio in theFig. 1. (A) Systolic blood pressure (mm Hg) measured by tail-cuff method (n=19–25 per g
right femoral artery. Data are shown as mean±SEM. (n=5–9 per group). * Pb0.05 vs. allhypertensive groups compared with the sham groups (Pb0.05; Fig. 3B),
with approximately 30% higher ratios in the untreated 2K1C group com-
pared with the sham group (Pb0.05; Fig. 3B). Tempol treatment attenu-
ated the increases in this ratio signiﬁcantly (Pb0.05 versus untreated
2K1C; Fig. 3B). In parallel with these results, we found increased septum
and LVwall thickness (11% and 21%, respectively) in untreated 2K1C rats
when compared with sham groups (Pb0.05). Tempol treatment pre-
vented these increases in hypertensive rats (Pb0.05 versus untreated
2K1C; Fig. 3A, C and D).
Fig. 4A shows representative photomicrographs of sections from
left ventricles, which were used to assess the minor diameter of myo-
cytes. This diameter was 30% greater in untreated hypertensive rats
compared with the sham group (Pb0.05; Fig. 4B). Tempol treatment
decreased this parameter by 17% (Pb0.05; Fig. 4B).4.4. Tempol treatment attenuates 2K1C-induced cardiac ﬁbrosis
Fig. 5A shows representative photomicrographs of sections from left
ventricles, which were used to assess the collagen surface. The myocar-
dial ﬁbrosis was observed in untreated 2K1C rats by an increase in the
amount of endomysial and perimysial collagen matrix (1.7±0.13)
when compared with the sham group (0.8±0.01; Pb0.05; Fig. 5B).roup). (B, C and D) Invasive blood pressure measured with catheters inserted into the
the other groups. # Pb0.05 for 2K1C+tempol group versus the sham groups.
Fig. 2. Increased maximum ascending (panel A; positive dP/dtmax) and declining (panel
B; negative dP/dtmax) rates of left ventricular pressure in untreated 2-kidney, 1-clip
(2K1C) rats compared with all the other groups. Data are shown as mean±SEM.
(n=5–8 per group). * Pb0.05 vs. the other groups.
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rats (1.2±0.07; Pb0.05; Fig. 5B).4.5. Tempol treatment inhibits 2K1C hypertension-induced oxidative stress
Weevaluated the effects of tempol treatments onROS levels in the left
ventricle of hypertensive rats. Fig. 6A shows representative ﬂuorescence
photomicrographs of left ventricular cryosections incubated with DHE.
We found higher ROS levels in untreated 2K1C rats compared with the
sham group (Pb0.05; Fig. 6B). Tempol treatment signiﬁcantly reduced
ROS in 2K1C rats when compared to the untreated 2K1C group
(Pb0.05; Fig. 6B).4.6. Tempol treatment inhibits 2K1C hypertension-induced TGF-beta
upregulation
Fig. 7A shows representative photomicrographs of TGF-beta ex-
pression. Higher TGF-beta levels were found in LV from 2K1C rats
compared with those found in the sham groups (Pb0.05; Fig. 7B).Treatment with tempol normalized 2K1C induced-cardiac TGF-beta
levels upregulation (Pb0.05; 7B).
4.7. Tempol treatment inhibits 2K1C hypertension-induced MMP activity
upregulation, but not MMP-2 expression
Fig. 8A shows representative photomicrographs of total gelatino-
lytic activity, MMP-2 expression, and their co-localization in the left
ventricular tissue. Higher total gelatinolytic activity was found in LV
from 2K1C rats compared with those found in the sham group
(Pb0.05; Fig. 8B). Treatment with antioxidant lowered LV gelatinoly-
tic activity (Pb0.05; 8B). Co-localization of gelatinolytic activity with
MMP-2 showed that part of the gelatinolytic activity is probably due
to MMP-2 activity.
Increased MMP-2 expression (by immunoﬂuorescence) was
found in all hypertensive groups as compared to the sham groups
(Pb0.05; Fig. 8C). Fig. 9A shows a representative SDS-PAGE gelatin
zymogram of left ventricle samples. While we found increased
MMP-2 levels in the 2K1C group compared with the sham group
(Pb0.05; Fig. 9B), we found no differences among the hypertensive
groups (PN0.05; Fig. 9B).
5. Discussion
The 2K1C hypertension experimental model is clearly dependent on
the activation of the renin–angiotensin–aldosterone system (RAAS),
and increased angiotensin II production has direct hypertrophic effects
that may be due to increased ROS formation [26]. Indeed, angiotensin II
promotes oxidative stress and increases TGF-β [27] levels andMMPs ac-
tivities [28]. Therefore antioxidant drugs could have important beneﬁ-
cial effects by downregulating these mechanisms.
In the present study, we examined whether antioxidant effects
exerted by tempol could prevent the cardiac hypertrophy and upregula-
tion of pro-ﬁbrotic factors (TGF-β andMMPs) in 2K1Chypertensive rats.
Our main ﬁndings were: (i) antioxidant treatment attenuated the in-
creases in blood pressure, the cardiac hypertrophy and ﬁbrosis found
in the 2K1C model, with prevention of cardiac dysfunction; (ii) while
tempol did not affect the increases in cardiac MMP-2 levels, it downre-
gulated gelatinolytic activity and TGF-β levels in the left ventricles of hy-
pertensive animals. These ﬁndings support the idea that oxidative stress
contributes to upregulation of TGF-β levels andMMPs activities in 2K1C
hypertension, and that antioxidant treatmentmay prevent the structur-
al and functional cardiac alterations of hypertension.
Consistent with known cardiac remodeling of extracellular matrix
and cellular alterations in hypertensive cardiac disease [2], we found
increased cardiac weight paralleling cardiomyocyte hypertrophy and
increased collagen deposition in hypertensive animals. These alter-
ations may result from critical involvement of activated RAAS, with
increased angiotensin II formation inducing cardiac hypertrophy
and ﬁbrosis via TGF-β activation [27]. Moreover, the increased oxida-
tive stress that we found in hypertensive rats may have enhanced
TGF-β gene expression and activated latent TGF-β, as previously
shown [17]. Conversely, tempol may have blunted this mechanism,
as suggested by lower ROS and TGF-β levels in hypertensive rats trea-
ted with tempol. These ﬁndings are in line with a previous study
showing that oxidative stress induces cardiomyocyte hypertrophy
and extracellular matrix alterations via TGF-β upregulation in hyper-
tension [14].
The contribution of TGF-β to ﬁbrosis in hypertension involves al-
tered regulation of MMPs activities, as previously shown [2,3,14].
While the precise mechanisms increasing cardiac MMPs activities
in 2K1C hypertension are uncertain, we found evidence that in-
creased ROS formation may be a major contributor to imbalanced
MMPs activities. In addition, TGF-β may stimulate ROS production
by numerous types of nonphagocytic cells including endothelial
cells, epithelial cells, smooth muscle cells, and ﬁbroblasts [17],
Fig. 3. Effects of tempol treatment on cardiacmorphological alterations induced by hypertension. (A) Representative photomicrographs of transverse heart sections used for left ventricle
area determination. (B) Body weight/heart weight ratio, (C) septumwall thickness, and (D) left ventricle wall thickness. Data are shown as mean±SEM. (N=6 per group). * Pb0.05 vs.
the other groups. # Pb0.05 vs. the sham groups.
169E. Rizzi et al. / International Journal of Cardiology 165 (2013) 165–173which potentially activate MMPs. In the present study, although
tempol had no effects on cardiac MMP-2 levels, it may have blunted
MMP-2 activation, since ROS directly activate MMPs, includingFig. 4. Antioxidant treatment attenuates hypertension-induced increases in myocyte diamete
magniﬁcation 400×). (B) Values of minor diameter of myocytes. Data are shown as mean±SEMMP-2 [15,16,29]. In addition, activation of MMPs by ROS is a multi-
stage process, and an initial activationmay take place without reduc-
tion in the molecular weight of MMPs [30], as it has been describedr. (A) Representative photomicrographs of sections from left ventricle myocytes (original
M. (N=4–6 per group). * Pb0.05 vs. the other groups. # Pb0.05 vs. the sham groups.
Fig. 5. Antioxidant treatment attenuates hypertension-induced ﬁbrosis. (A) Representative photomicrographs of sections from left ventricle picrosirius red-stained sections (orig-
inal magniﬁcation 400×). (B) Values of volume fraction (%) with ﬁbrosis in the left ventricular and septum myocardium. The mean of 15 ﬁelds per region were evaluated for each
animal. Data are shown as mean±SEM. (N=4–6 per group). * Pb0.05 vs. the other groups.
170 E. Rizzi et al. / International Journal of Cardiology 165 (2013) 165–173for MMP-2 [30,31]. Indeed, ROS may interact with thiol groups of the
propeptide and with the zinc ion of the catalytic site, thus resulting
in activation of the full-length enzyme. Therefore, tempol may have
inhibited MMPs activation as a result of its antioxidant effects. More-
over, tempol may have inhibited MMPs activities by promoting the
inhibitory properties of the tissue inhibitors of matrix metalloprotei-
nases (TIMPs) in the LV of hypertensive rats. Supporting this sugges-
tion, the ability of TIMPs to inhibit MMPs was lost after treatment
with ONOO− or HOCl [32–34]. In a context of impaired TIMP func-
tion associated with increased ROS levels, as we found in the hearts
of 2K1C rats, the imbalance between MMPs and TIMPs favors in-
creased MMP activity. Therefore, our results strongly suggest that
tempol may have downregulated MMPs and exerted protective ef-
fects that are similar to those previously found after MMPs inhibi-
tion, which attenuated 2K1C-induced functional and morphological
cardiac alterations [35].Fig. 6. Effects of antioxidant treatment on cardiac reactive oxygen species production. (A) Re
tricular cryosections incubated with DHE. Red ﬂuorescence represents O2− production. (B) Q
per group). * Pb0.05 vs. the other groups.Other antioxidant drugs may exert similar effects to those exerted
by tempol in the present study. Indeed, apocynin attenuated pressure
overload-induced cardiac dysfunction, and this effect was associated
with reduced cardiac expression of MMPs and TGF-β1 [14], although
this has not been shown in the 2K1C model. In fact, this suggestion
was apparently valid with respect to the vascular alterations associat-
ed with this model [23]. It is also possible that antihypertensive drugs
with antioxidant effects may downregulate MMPs and prevent car-
diovascular remodeling, as previously suggested [36–40]. However,
this suggestion remains to be proved.
In conclusion, our results suggest that tempol protects against
2K1C hypertension-induced structural and functional alterations of
the heart. These protective effects are associated with downregula-
tion of TGF-β and MMPs in the heart. Our ﬁndings suggest that anti-
oxidants may prevent the activation of key mechanisms involved in
hypertensive cardiac hypertrophy.presentative ﬂuorescence photomicrographs (original magniﬁcation 400×) of left ven-
uantiﬁcation of left ventricular ﬂuorescence. Data are shown as mean±SEM (n=4–7
Fig. 7. TGF-β expression in the left ventricles from rats (original magniﬁcation 400×). (A) Representative photomicrographs (immunoﬂuorescence) of TGF-β expression. (B) Red ﬂuores-
cence intensity corresponding to TGF-β levels in the left ventricles from rats. Values are shown as means±SEM. (n=4–6 per group). * Pb0.05 vs. the other groups.
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